PDCD1 and neoplasm: Consequently, anti-PD-1 immune checkpoint inhibitors may be able to enter and inhibit the binding of PD-L1 (programmed cell death ligand 1) on tumor cells and the PD-1 receptor on T cells in at least some areas of BM.